Table 3

Efficacy assessment of the phase 2 study

CharacteristicsORR (%)CR (%)SD (%)PD (%)Not evaluable (%)*
Phase 2 (n = 113)68 (60.2)46 (40.7)11 (9.7)30 (26.5)4 (3.5)
IPI
 0–1 (n = 34)23 (67.6)18 (52.9)3 (8.8)7 (20.6)1 (2.9)
 2 (n = 33)20 (60.6)13 (39.4)6 (18.2)7 (21.2)0 (0)
 3 (n = 24)14 (58.3)7 (29.2)1 (4.2)8 (33.3)1 (4.2)
 4–5 (n = 22)11 (50.0)8 (36.4)1 (4.5)9 (40.9)2 (9.1)
Pathology subtypes
 AITL (n = 41)27 (65.9)17 (41.5)4 (9.8)8 (19.5)2 (4.9)
 PTCL-NOS (n = 48)26 (54.2)20 (41.7)5 (10.4)16 (33.3)1 (2.1)
 ALCL (ALK-) (n = 17)13 (76.5)8 (47.1)2 (2.8)2 (2.8)0 (0)
 EATL (n = 7)2 (28.6)1 (14.3)0 (0)4 (57.1)1 (14.3)

*Patients without efficacy assessments due to premature discontinuation by AEs.

ORR, overall response rate; CR, complete response; SD, stable disease; PD, progressive disease; IPI, international prognostic index; AITL, angioimmunoblastic T cell lymphoma; PTCL-NOS, peripheral T cell lymphoma-not otherwise specified; ALCL, anaplastic large cell lymphoma; EATL, enteropathy-associated T-cell lymphoma; AE, adverse event.